8-K Announcements
6Material company update
May 15, 2026·SEC
Material company update
May 14, 2026·SEC
Material company update
May 7, 2026·SEC
Profound Medical Corp.(PROF)Earnings, Financials & Key Ratios
PROF•NASDAQ
Price updated Jun 19, 2026
AboutProfound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops magnetic resonance guided ablation procedures for treatment of prostate disease, uterine fibroids, and palliative pain treatment in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system used for magnetic resonance imaging scanner in hospitals and treatment facilities. The company also offers Sonalleve, a therapeutic platform for the treatment of uterine fibroids and palliative pain relief associated with metastases in bone, as well as non-invasive treatment of uterine fibroids. Profound Medical Corp. is headquartered in Mississauga, Canada.Show more
- Revenue$16M+58.3%
- EBITDA-$41M-33.1%
- Net Income-$43M-60.8%
- EPS (Diluted)-1.43-33.6%
- Gross Margin70.77%+7.4%
- EBITDA Margin-252.79%+16.0%
- Operating Margin-256.27%+17.2%
- Net Margin-264.44%-1.5%
- ROE-56.23%+2.7%
PROF Key Insights
Profound Medical Corp. (PROF) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓High quality earnings: Operating CF exceeds net income
- ✓Strong 5Y sales CAGR of 17.1%
✗Weaknesses
- ✗Profits declining 14.5% over 5 years
- ✗Negative free cash flow
- ✗Shares diluted 22.1% in last year
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when PROF posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
PROF Price & Volume
Profound Medical Corp. (PROF) stock price & volume — 10-year historical chart
Loading chart...
PROF Growth Metrics
Profound Medical Corp. (PROF) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years17.12%
3 Years34.06%
TTM33.76%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-2.18%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-1.63%
Return on Capital
10 Years-63.13%
5 Years-46.43%
3 Years-51.3%
Last Year-33.23%
PROF Recent Earnings
Profound Medical Corp. (PROF) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 6/12 qtrs (50%)●Beat Revenue 2/12 qtrs (17%)
Q2 2026Latest
May 7, 2026Metric
Actual
Est
EPS
$0.19+20.8%
$0.24
Rev
$5M+10.0%
$5M
Q2 2026
Mar 5, 2026Metric
Actual
Est
EPS
$0.27+0.0%
$0.27
Rev
$6M-22.0%
$8M
Q4 2025
Nov 13, 2025Metric
Actual
Est
EPS
$0.26+31.6%
$0.38
Rev
$5M-50.3%
$11M
Q3 2025
Aug 14, 2025Metric
Actual
Est
EPS
$0.52-20.9%
$0.43
Rev
$2M-53.3%
$5M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 7, 2026 | $0.19vs $0.24+20.8% | $5Mvs $5M+10.0% |
| Q2 2026 | Mar 5, 2026 | $0.27vs $0.27+0.0% | $6Mvs $8M-22.0% |
| Q4 2025 | Nov 13, 2025 | $0.26vs $0.38+31.6% | $5Mvs $11M-50.3% |
| Q3 2025 | Aug 14, 2025 | $0.52vs $0.43-20.9% | $2Mvs $5M-53.3% |
Based on last 12 quarters of dataView full earnings history →
PROF Peer Comparison
Profound Medical Corp. (PROF) competitors in Imaging, radiation, and oncology devices — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 ISRG | 144.48B | 406.78 | 51.69 | 20.51% | 28.15% | 16.89% | 0.02 | |
 NVCR | 1.62B | 14.28 | -11.70 | 8.28% | -25.66% | -50.82% | 0.85 | |
 AEYE | 78.83M | 6.31 | -25.24 | 14.52% | -9.05% | -70.95% | 2.75 | |
 EDAP | 178.23M | 4.76 | -6.10 | 10.34% | -41.7% | -148.9% | 1.43 | |
 ARAY | 41.39M | 0.35 | -22.45 | 2.68% | -10.76% | -77.48% | 2.17 | |
 GKOS | 7.65B | 130.68 | -39.84 | 32.33% | -34.34% | -26.46% | 0.21 | |
 NNOX | 109.19M | 1.67 | -1.84 | 13.91% | -452.82% | -35.55% | 0.04 | |
 PHG | 25.5B | 26.78 | 25.02 | -1.04% | 5.49% | 8.96% | 0.74 |
Compare PROF vs Peers
Profound Medical Corp. (PROF) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
PROF Income Statement
Profound Medical Corp. (PROF) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 3.9M | 1.91M | 4.17M | 7.3M | 6.87M | 6.68M | 7.2M | 10.17M | 16.1M | 18.74M |
Revenue Growth % | - | -51.01% | 118.47% | 74.99% | -5.9% | -2.79% | 7.75% | 41.23% | 58.33% | 33.76% |
Cost of Goods Sold | 2.41M | 1.31M | 1.78M | 3.83M | 3.92M | 3.66M | 2.82M | 3.47M | 4.71M | 5.42M |
COGS % of Revenue | 61.82% | 68.34% | 42.74% | 52.44% | 57.05% | 54.78% | 39.13% | 34.11% | 29.23% | - |
Gross Profit | 1.49M▲ 0% | 604.82K▼ 59.4% | 2.39M▲ 295.2% | 3.47M▲ 45.4% | 2.95M▼ 15.0% | 3.02M▲ 2.3% | 4.38M▲ 45.1% | 6.7M▲ 52.9% | 11.39M▲ 70.1% | 13.32M▲ 0% |
Gross Margin % | 38.18% | 31.66% | 57.26% | 47.56% | 42.95% | 45.22% | 60.87% | 65.89% | 70.77% | 71.07% |
Gross Profit Growth % | 896.19% | -59.38% | 295.16% | 45.36% | -15.03% | 2.34% | 45.05% | 52.88% | 70.07% | - |
Operating Expenses | 15.51M | 15.43M | 17.29M | 22.34M | 33.24M | 35.15M | 33M | 38.17M | 52.65M | 51.32M |
OpEx % of Revenue | 397.67% | 807.7% | 414.33% | 305.82% | 483.68% | 526.07% | 458.37% | 375.46% | 327.04% | - |
Selling, General & Admin | 7.84M | 7.89M | 7.9M | 12.43M | 17.97M | 17.93M | 18.62M | 22.02M | 32.05M | 30.34M |
SG&A % of Revenue | 201.06% | 413.03% | 189.19% | 170.11% | 261.4% | 268.42% | 258.66% | 216.61% | 199.1% | - |
Research & Development | 7.66M | 7.54M | 9.4M | 9.91M | 15.28M | 14.69M | 14.38M | 16.15M | 20.6M | 20.98M |
R&D % of Revenue | 196.52% | 394.48% | 225.13% | 135.71% | 222.28% | 219.88% | 199.71% | 158.85% | 127.94% | - |
Other Operating Expenses | 3.65K | 3.75K | 0 | 0 | 0 | 2.52M | 0 | 0 | 0 | 0 |
Operating Income | -17.63M▲ 0% | -14.83M▲ 15.9% | -14.9M▼ 0.5% | -18.86M▼ 26.6% | -30.29M▼ 60.6% | -32.13M▼ 6.1% | -28.62M▲ 10.9% | -31.47M▼ 10.0% | -41.25M▼ 31.1% | -38M▲ 0% |
Operating Margin % | -451.94% | -776.04% | -357.07% | -258.26% | -440.72% | -480.86% | -397.5% | -309.57% | -256.27% | -202.76% |
Operating Income Growth % | -12.7% | 15.88% | -0.52% | -26.56% | -60.58% | -6.06% | 10.93% | -9.99% | -31.07% | - |
EBITDA | -16.75M | -13.15M | -13.39M | -17.32M | -28.41M | -30.52M | -27.47M | -30.58M | -40.69M | -37.5M |
EBITDA Margin % | -429.47% | -688.14% | -320.87% | -237.2% | -413.39% | -456.85% | -381.58% | -300.81% | -252.79% | -200.12% |
EBITDA Growth % | -8.39% | 21.51% | -1.87% | -29.36% | -63.99% | -7.43% | 10% | -11.33% | -33.06% | 57.46% |
D&A (Non-Cash Add-back) | 876.42K | 1.68M | 1.51M | 1.54M | 1.88M | 1.6M | 1.15M | 891.06K | 560K | 495.61K |
EBIT | -13.84M | -14.32M | -14.04M | -21.03M | -30.53M | -28.21M | -27.93M | -26.48M | -41.25M | -38M |
Net Interest Income | -970.25K | -400.18K | -675K | 149K | 136.78K | 882.59K | 872K | 1.37M | 0 | 371.78K |
Interest Income | 101.58K | 355.2K | 363K | 692K | 203.2K | 1.05M | 1.64M | 1.37M | 0 | 371.78K |
Interest Expense | 1.07M | 755.37K | 1.04M | 543K | 66.41K | 167.1K | 770K | 0 | 0 | 0 |
Other Income/Expense | 2.72M | -247.72K | -171K | -2.71M | -303K | 3.74M | -81K | 4.99M | -1.06M | -568.75K |
Pretax Income | -14.91M▲ 0% | -15.07M▼ 1.1% | -15.07M▼ 0.0% | -21.58M▼ 43.1% | -30.59M▼ 41.8% | -28.38M▲ 7.2% | -28.7M▼ 1.1% | -26.48M▲ 7.7% | -42.32M▼ 59.8% | -38.57M▲ 0% |
Pretax Margin % | -382.26% | -789.01% | -361.16% | -295.41% | -445.13% | -424.82% | -398.62% | -260.47% | -262.88% | -205.8% |
Income Tax | 58.94K | 169.44K | 147K | 45K | 105K | 287K | -128K | -1.9K | 252K | 235.65K |
Effective Tax Rate % | -0.4% | -1.12% | -0.98% | -0.21% | -0.34% | -1.01% | 0.45% | 0.01% | -0.6% | -0.61% |
Net Income | -14.97M▲ 0% | -15.24M▼ 1.8% | -15.22M▲ 0.1% | -21.62M▼ 42.0% | -30.7M▼ 42.0% | -28.67M▲ 6.6% | -28.57M▲ 0.3% | -26.48M▲ 7.3% | -42.57M▼ 60.8% | -38.8M▲ 0% |
Net Margin % | -383.77% | -797.88% | -364.69% | -296.03% | -446.66% | -429.11% | -396.85% | -260.45% | -264.44% | -207.06% |
Net Income Growth % | -23.22% | -1.84% | 0.15% | -42.04% | -41.98% | 6.61% | 0.35% | 7.31% | -60.76% | -2.18% |
Net Income (Continuing) | -18.82M | -15.24M | -15.22M | -21.62M | -30.7M | -28.67M | -28.57M | -26.48M | -42.57M | -38.8M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -2.44▲ 0% | -1.52▲ 37.7% | -1.39▲ 8.6% | -1.25▲ 10.1% | -1.50▼ 20.0% | -1.38▲ 8.0% | -1.35▲ 2.2% | -1.07▲ 20.7% | -1.43▼ 33.6% | -1.07▲ 0% |
EPS Growth % | 16.72% | 37.7% | 8.55% | 10.07% | -20% | 8% | 2.17% | 20.74% | -33.64% | -1.63% |
EPS (Basic) | -2.44 | -1.52 | -1.39 | -1.25 | -1.50 | -1.38 | -1.35 | -1.07 | -1.43 | - |
Diluted Shares Outstanding | 6.14M | 10.04M | 11.09M | 17.29M | 20.47M | 20.83M | 21.18M | 24.77M | 30.23M | 36.3M |
Basic Shares Outstanding | 6.14M | 10.04M | 11.09M | 17.29M | 20.46M | 20.83M | 21.18M | 24.77M | 30.23M | 36.3M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
PROF Balance Sheet
Profound Medical Corp. (PROF) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 14M | 27.84M | 22.84M | 97.74M | 77.02M | 62.02M | 41.9M | 69.06M | 104.21M | 69.76M |
Cash & Short-Term Investments | 8.83M | 22.53M | 14.82M | 83.91M | 67.06M | 46.52M | 26.21M | 54.91M | 81.8M | 50.46M |
Cash Only | 8.83M | 22.53M | 14.82M | 83.91M | 67.06M | 46.52M | 26.21M | 54.91M | 81.8M | 50.46M |
Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts Receivable | 3.57M | 1.52M | 3.31M | 7.43M | 1.41M | 6.34M | 7.29M | 7.04M | 9.86M | 9.45M |
Days Sales Outstanding | 334.27 | 289.58 | 289.84 | 371.35 | 74.88 | 346.59 | 369.51 | 252.91 | 223.59 | 157.66 |
Inventory | 1.14M | 2.67M | 3.67M | 5.33M | 7.4M | 7.94M | 6.99M | 5.8M | 11.28M | 9.03M |
Days Inventory Outstanding | 172.27 | 745.31 | 751.72 | 508.05 | 689.13 | 791.93 | 905.57 | 610.53 | 875.3 | 622.85 |
Other Current Assets | 458.07K | 224.87K | 1.03M | 1.07M | 1.15M | 0 | 0 | 0 | 1.27M | 813.67K |
Total Non-Current Assets | 8.17M | 6.34M | 7.27M | 6.86M | 9.64M | 2.4M | 2.06M | 1.17M | 88.73M | 3.94M |
Property, Plant & Equipment | 1.37M | 886.44K | 2.22M | 2.28M | 1.9M | 1.72M | 1.57M | 821.01K | 225K | 3.59M |
Fixed Asset Turnover | 2.84x | 2.16x | 1.88x | 3.20x | 3.61x | 3.89x | 4.59x | 12.38x | 71.55x | 15.07x |
Goodwill | 2.71M | 2.5M | 2.63M | 2.68M | 2.69M | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 4.09M | 2.95M | 2.41M | 1.9M | 1.43M | 680K | 490K | 261K | 138K | 129.42K |
Long-Term Investments | 0 | 0 | 0 | 0 | 3.62M | 0 | 0 | 0 | 410.89K | 561.38K |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 87.96M | 0 |
Total Assets | 22.17M▲ 0% | 34.18M▲ 54.2% | 30.11M▼ 11.9% | 104.6M▲ 247.4% | 86.66M▼ 17.2% | 64.42M▼ 25.7% | 43.96M▼ 31.8% | 70.23M▲ 59.8% | 192.94M▲ 174.7% | 73.7M▲ 0% |
Asset Turnover | 0.18x | 0.06x | 0.14x | 0.07x | 0.08x | 0.10x | 0.16x | 0.14x | 0.08x | 0.21x |
Asset Growth % | 25.77% | 54.15% | -11.91% | 247.42% | -17.15% | -25.66% | -31.77% | 59.78% | 174.71% | 168.52% |
Total Current Liabilities | 8.53M | 5.79M | 8.24M | 4.81M | 4.15M | 4.18M | 6.37M | 6.57M | 8.32M | 10.64M |
Accounts Payable | 4.04M | 2.87M | 3.03M | 3.38M | 3.18M | 2.03M | 865K | 1.32M | 2.14M | 2.15M |
Days Payables Outstanding | 611.71 | 802.93 | 620.55 | 322.31 | 295.62 | 202.74 | 112.08 | 138.61 | 166.07 | 100.25 |
Short-Term Debt | 3.74M | 983.52K | 4.17M | 312K | 249.66K | 523K | 2.1M | 1.74M | 291.73K | 4.59M |
Deferred Revenue (Current) | 191.9K | 229.48K | 504.93K | 358K | 476.35K | 471K | 721K | 419K | 0 | 2.2M |
Other Current Liabilities | 586.19K | 1.48M | 521.75K | 744K | 247.66K | 621K | 1.42M | 1.03M | 5.83M | 1.69M |
Current Ratio | 1.64x | 4.81x | 2.77x | 20.32x | 18.56x | 14.82x | 6.58x | 10.52x | 12.52x | 6.56x |
Quick Ratio | 1.51x | 4.35x | 2.33x | 19.22x | 16.78x | 12.92x | 5.48x | 9.64x | 11.17x | 5.71x |
Cash Conversion Cycle | -105.16 | 231.96 | 421.01 | 557.09 | 468.39 | 935.77 | 1.16K | 724.83 | 932.83 | 680.27 |
Total Non-Current Liabilities | 2.4M | 8.84M | 7.48M | 2.44M | 2M | 8.23M | 6.36M | 3.25M | 93.63M | 3.44M |
Long-Term Debt | 352.98K | 10.62M | 5.18M | 0 | 0 | 6.65M | 5M | 2.92M | 6.16M | 0 |
Capital Lease Obligations | 0 | -2.82M | 1.64M | 1.36M | 1.13M | 817K | 504K | 203K | 0 | 2.97M |
Deferred Tax Liabilities | -284.95K | 250.64K | 0 | 0 | 0 | 0 | 59K | 0 | 86.83M | 86.83M |
Other Non-Current Liabilities | 2.04M | -2.3M | 14.65K | 0 | 0 | 0 | 73K | 71K | 108.2K | 92.3K |
Total Liabilities | 10.93M | 14.63M | 15.71M | 7.25M | 6.15M | 12.42M | 12.73M | 9.81M | 101.95M | 14.08M |
Total Debt | 4.09M | 8.78M | 10.99M | 1.68M | 1.38M | 8.23M | 7.87M | 5.12M | 6.45M | 7.49M |
Net Debt | -4.74M | -13.75M | -3.84M | -82.24M | -65.69M | -38.29M | -18.35M | -49.79M | -75.34M | -42.97M |
Debt / Equity | 0.36x | 0.45x | 0.76x | 0.02x | 0.02x | 0.16x | 0.25x | 0.08x | 0.07x | 0.13x |
Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.20x |
Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | 1.15x |
Interest Coverage | -12.91x | -18.96x | -13.52x | -38.74x | -459.67x | -168.80x | -36.27x | - | - | - |
Total Equity | 11.25M▲ 0% | 19.55M▲ 73.8% | 14.39M▼ 26.4% | 97.35M▲ 576.4% | 80.51M▼ 17.3% | 52M▼ 35.4% | 31.22M▼ 40.0% | 60.42M▲ 93.5% | 90.99M▲ 50.6% | 59.62M▲ 0% |
Equity Growth % | 1.88% | 73.84% | -26.37% | 576.36% | -17.3% | -35.41% | -39.96% | 93.51% | 50.59% | 44.57% |
Book Value per Share | 1.83 | 1.95 | 1.30 | 5.63 | 3.93 | 2.50 | 1.47 | 2.44 | 3.01 | 1.64 |
Total Shareholders' Equity | 11.25M | 19.55M | 14.39M | 97.35M | 80.51M | 52M | 31.22M | 60.42M | 90.99M | 59.62M |
Common Stock | 78.22M | 88.79M | 100.46M | 211.53M | 219.28M | 205.82M | 222.21M | 281.55M | 443.54M | 325.23M |
Retained Earnings | -71.79M | -81.52M | -101.07M | -129.99M | -160.48M | -189.36M | -217.35M | -245.17M | -394.1M | -295.76M |
Treasury Stock | -4.85M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | -46.07K | -21.07K | -90.37K | 4.57M | 4.74M | 16.84M | 5.57M | 2.74M | 6.88M | 4.03M |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
PROF Cash Flow Statement
Profound Medical Corp. (PROF) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -11.81M | -13.43M | -15.45M | -20.57M | -22.36M | -25.8M | -22.61M | -23.45M | -53.34M | -38.67M |
Operating CF Margin % | -302.87% | -703.02% | -370.07% | -281.68% | -325.33% | -386.17% | -314.06% | -230.67% | -331.36% | - |
Operating CF Growth % | -9.48% | -13.71% | -15% | -33.19% | -8.68% | -15.38% | 12.37% | -3.73% | -127.45% | -185.31% |
Net Income | -14.97M | -15.24M | -15.57M | -21.62M | -30.7M | -28.67M | -28.32M | -27.82M | 42.32M | -38.8M |
Depreciation & Amortization | 693.31K | 1.23M | 1.55M | 1.54M | 1.88M | 1.6M | 929K | 936K | 0 | 497.98K |
Stock-Based Compensation | 1.06M | 797.49K | 0 | 3.02M | 7.21M | 4.24M | 3.42M | 2.58M | 0 | 0 |
Deferred Taxes | 0 | -70.94K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | 1.9M | 847.17K | 1.72M | 1.13M | 132K | 2.66M | 828K | 255K | -93.27M | 5.62M |
Working Capital Changes | -501.61K | -990.83K | -3.15M | -4.63M | -877K | -5.63M | 540K | 591K | -2.39M | -5.69M |
Change in Receivables | -3.17M | 1.15M | -872.97K | -3.85M | 2M | -1.42M | -956K | 186K | -240.14K | -3.46M |
Change in Inventory | -806.63K | -1.62M | -873.6K | -2.14M | -2.49M | -1.86M | 353K | 656K | -3.94M | -2.84M |
Change in Payables | 2.68M | -857.06K | -18.63K | 102K | -356K | -566K | 1.35M | 815K | 527.74K | 383K |
Cash from Investing | -793.18K | 0 | -192.79K | -350K | -593K | 0 | 0 | 0 | -337.87K | -246.24K |
Capital Expenditures | -369.5K | 0 | -192.79K | -350K | -32K | 0 | 0 | 0 | -337.87K | -246.24K |
CapEx % of Revenue | 9.47% | - | 4.62% | 4.79% | 0.47% | - | - | - | 2.1% | 1.31% |
Acquisitions | -423.68K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | 0 | 0 | 0 | 0 | -561K | 0 | 0 | 0 | 0 | 0 |
Cash from Financing | 6.12M | 27.81M | 6.8M | 87.43M | 5.95M | 7.03M | 1.76M | 54.7M | 57.43M | 42.24M |
Debt Issued (Net) | -2.29M | 9.05M | -12.5K | -9.61M | -386K | 6.92M | -912K | -2.56M | -1.82M | -1.03M |
Equity Issued (Net) | 9.01M | 25.33M | 8.08M | 85.52M | 0 | 0 | 0 | 62.11M | 59.26M | 43.19M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | -604.21K | -6.57M | -1.27M | 11.52M | 6.33M | 114K | 2.67M | -4.85M | 0 | 75K |
Net Change in Cash | -7.74M▲ 0% | 14.38M▲ 285.8% | -7.64M▼ 153.2% | 69.11M▲ 1004.0% | -16.76M▼ 124.3% | -20.64M▼ 23.1% | -20.3M▲ 1.6% | 28.7M▲ 241.3% | 6.5M▼ 77.4% | 4.03M▲ 0% |
Free Cash Flow | -12.18M▲ 0% | -13.43M▼ 10.3% | -15.45M▼ 15.0% | -20.92M▼ 35.5% | -22.95M▼ 9.7% | -25.8M▼ 12.4% | -22.61M▲ 12.4% | -23.45M▼ 3.7% | -53.59M▼ 128.5% | -38.85M▲ 0% |
FCF Margin % | -312.34% | -703.02% | -370.07% | -286.47% | -333.96% | -386.17% | -314.06% | -230.67% | -332.89% | -207.31% |
FCF Growth % | -5.03% | -10.26% | -15% | -35.46% | -9.7% | -12.4% | 12.37% | -3.73% | -128.49% | -44.05% |
FCF per Share | -1.98 | -1.34 | -1.39 | -1.21 | -1.12 | -1.24 | -1.07 | -0.95 | -1.77 | -1.07 |
FCF Conversion (FCF/Net Income) | 0.79x | 0.88x | 1.01x | 0.95x | 0.73x | 0.90x | 0.79x | 0.89x | 1.25x | 1.00x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 43K | 669K | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 55K | 160K | 0 | 0 | 0 |
PROF Key Ratios
Profound Medical Corp. (PROF) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | -134.34% | -99.01% | -89.69% | -38.7% | -34.52% | -43.27% | -68.65% | -57.79% | -56.23% | -69.91% |
Return on Invested Capital (ROIC) | -378.57% | -180.77% | -136.7% | -110.22% | -151.78% | -168.85% | -161.4% | -200.82% | -235.5% | -233.77% |
Gross Margin | 38.18% | 31.66% | 57.26% | 47.56% | 42.95% | 45.22% | 60.87% | 65.89% | 70.77% | 71.07% |
Net Margin | -383.77% | -797.88% | -364.69% | -296.03% | -446.66% | -429.11% | -396.85% | -260.45% | -264.44% | -207.06% |
Debt / Equity | 0.36x | 0.45x | 0.76x | 0.02x | 0.02x | 0.16x | 0.25x | 0.08x | 0.07x | 0.13x |
Interest Coverage | -12.91x | -18.96x | -13.52x | -38.74x | -459.67x | -168.80x | -36.27x | - | - | - |
FCF Conversion | 0.79x | 0.88x | 1.01x | 0.95x | 0.73x | 0.90x | 0.79x | 0.89x | 1.25x | 1.00x |
Revenue Growth | - | -51.01% | 118.47% | 74.99% | -5.9% | -2.79% | 7.75% | 41.23% | 58.33% | 33.76% |
Related:PROF Dividend History·PROF Revenue History·PROF Price History·PROF P/E History·PROF Financial Ratios·PROF Institutional Holders
PROF SEC Filings & Documents
Profound Medical Corp. (PROF) SEC filings — annual & quarterly reports (10-K, 10-Q)
PROF Frequently Asked Questions
Profound Medical Corp. (PROF) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Profound Medical Corp. (PROF) reported $18.7M in revenue for fiscal year 2025.
Profound Medical Corp. (PROF) grew revenue by 58.3% over the past year. This is strong growth.
Profound Medical Corp. (PROF) reported a net loss of $38.8M for fiscal year 2025.
Dividend & Returns
Profound Medical Corp. (PROF) has a return on equity (ROE) of -56.2%. Negative ROE indicates the company is unprofitable.
Profound Medical Corp. (PROF) had negative free cash flow of $38.9M in fiscal year 2025, likely due to heavy capital investments.